Home›Trial›NCT05791201
🔬NCT05791201Phase 1Phase 2ACTIVE NOT RECRUITING

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Study Summary

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

Conditions
Type 1 Diabetes
Interventions / Drugs
VX-264
View on ClinicalTrials.gov ↗
Sponsor
VRTX
Vertex Pharmaceuticals
Gene Therapy
C55/100
Study Details
Enrollment7 participants
Primary Completion—
Lead SponsorVertex Pharmaceuticals Incorporated
Data Retrieved2026-04-11 02:55:58.035335+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.